Try our beta test site
494 studies found for:    PD-1
Show Display Options
Rank Status Study
21 Terminated Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Autologous Stem Cell Transplant;   Drug: Melphalan;   Drug: Lenalidomide;   Drug: MK-3475
22 Recruiting A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Intervention: Biological: TSR-042
23 Recruiting A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.
Condition: Melanoma
Intervention: Radiation: stereotactic body radiotherapy
24 Completed Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Condition: Neoplasms by Site
Interventions: Biological: Denenicokin;   Biological: Nivolumab
25 Recruiting Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1
Condition: Cancer
Interventions: Other: Biological samples;   Drug: Anti PD1/PDL1 treatment
26 Completed PD-1/PD-L1 Pathway Study on Septic Patients
Condition: Sepsis
Intervention:
27 Not yet recruiting A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207)
Conditions: Advanced or Metastatic Solid Tumors;   Advanced or Metastatic Colorectal Cancer (CRC);   Pancreatic Ductal Adenocarcinoma (PDAC);   Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous);   Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor;   Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor
Interventions: Drug: Epacadostat;   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-Fluorouracil;   Drug: Gemcitabine;   Drug: nab-Paclitaxel;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Cyclophosphamide
28 Recruiting Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Radiation: Radiotherapy;   Biological: Rituximab;   Biological: Autologous dendritic cells;   Biological: GM-CSF;   Biological: Pembrolizumab
29 Recruiting A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Condition: Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Interventions: Biological: ONCOS-102;   Drug: Cyclophosphamide;   Drug: Pembrolizumab
30 Suspended Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: CT-011 (Anti-PD1 Antibody);   Other: Sipuleucel-T (Provenge);   Drug: Cyclophosphamide
31 Recruiting Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Conditions: Melanoma (Skin);   Skin Cancer
Interventions: Drug: Nivolumab;   Procedure: Surgery to Remove Tumor for Growth of TIL;   Drug: CD137;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL Infusion;   Drug: Interleukin-2
32 Active, not recruiting 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MK-3475;   Drug: Pomalidomide;   Drug: Dexamethasone
33 Not yet recruiting Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Nivolumab;   Radiation: Radiation
34 Recruiting A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
Condition: Advanced Melanoma
Intervention: Drug: Pembrolizumab
35 Recruiting Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
Conditions: Breast Neoplasms;   Bone Neoplasms
Interventions: Radiation: Stereotactic Ablative Body Radiosurgery (SABR);   Drug: MK-3475
36 Not yet recruiting Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
Conditions: Carcinoma, Non-small-cell Lung;   Mesothelioma;   Pancreatic Neoplasms
Interventions: Drug: Defactinib;   Drug: Pembrolizumab
37 Recruiting Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
Condition: Renal Cell Carcinoma
Interventions: Drug: Interleukin-2;   Drug: Nivolumab
38 Not yet recruiting A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
Condition: Hepatocellular Carcinoma (HCC)
Interventions: Biological: Pexastimogene Devacirepvec (Pexa Vec);   Drug: Nivolumab
39 Active, not recruiting Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
Conditions: Influenza Virus Vaccine Adverse Reaction (Disorder);   Influenza;   Malignancy
Intervention: Biological: influenza vaccination
40 Recruiting Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Condition: Neoplasms by Site
Interventions: Biological: BMS-986016;   Biological: BMS-936558

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.